1112 On Other Exchanges
1112 is not on other exchanges.

biostime international holdi (1112) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOSTIME INTERNATIONAL HOLDI (1112)

Related News

No related news articles were found.

biostime international holdi (1112) Related Businessweek News

No Related Businessweek News Found

biostime international holdi (1112) Details

Biostime International Holdings Limited, an investment holding company, manufactures and sells pediatric nutritional and baby care products primarily in the People’s Republic of China. The company operates through Infant Formulas, Adult Nutrition and Care Products, and Other Pediatric Products segments. The Infant Formulas segment produces infant formulas for children under seven years old and milk formulas for expectant and nursing mothers. The Adult Nutrition and Care Products segment offers vitamins, health supplements, and skin care and sports nutrition products for adults. The Other Pediatric Products segment produces probiotic supplements, dried baby food products, and nutrition supplements. The company is also involved in the research, development, and processing of meat, fruit, and vegetable powder and candy; research, development, manufacture, and sale of health products and nutritional foods; sale of personal care products for infants and adults; wholesale, retail, import, and export of personal care products for infants; manufacture of organic baby foods and baby care products; trading of infant food and nutritional products; early childhood education advisory business; and trading of related baby supplies, as well as offers online software and information technology services. In addition, it provides packaging, digital media, and advertising services. The company offers its products and services under the Biostime, Adimil, BMcare, Parenting Power, and Mama100 brands. The company was founded in 1999 and is headquartered in Guangzhou, China. Biostime International Holdings Limited is a subsidiary of Biostime Pharmaceuticals (China) Limited.

Founded in 1999

biostime international holdi (1112) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: CNY5.0M
Compensation as of Fiscal Year 2016.
biostime international holdi
Biostime International Holdings Limited Announces Unaudited Consolidated Revenue Results for the Quarter Ended 31 March 2017

Biostime International Holdings Limited announced unaudited consolidated revenue results for the quarter ended 31 March 2017. For the quarter, total revenue was RMB 1,560.2 million against RMB 1,469.0 million a year ago.

Biostime International Holdings Limited Reports Consolidated Earnings Results for the Year Ended December 31, 2016

Biostime International Holdings Limited reported consolidated earnings results for the year ended December 31, 2016. For the period, the company’s revenue was CNY 6,505,616,000 against CNY 4,818,561,000 a year ago. Profit before tax was CNY 1,456,520,000 against CNY 502,748,000 a year ago. Profit attributable to owners of the parent was CNY 954,396,000 against CNY 250,687,000 a year ago. Diluted earnings per share attributable to ordinary equity holders of the parent were CNY 1.50 against CNY 0.40 a year ago. Capital expenditure CNY 103,135,000 against CNY 2,793,653,000 a year ago. EBITDA for the period increased to CNY 2,043.1 million from CNY 626.4 million for the year ended 31 December 2015. Net cash generated from operating activities was CNY 1,543.2 million, resulting from the pre-tax cash from operation of CNY 1,944.3 million, minus the income tax paid of CNY 401.1 million.

Biostime International Holdings Limited, Annual General Meeting, May 12, 2017

Biostime International Holdings Limited, Annual General Meeting, May 12, 2017, at 09:30 China Standard Time. Location: Marina Room II, 2/F., The Excelsior 281 Gloucester Road, Causeway Bay Hong Kong Agenda: To receive, consider and adopt the consolidated audited financial statements of the company and its subsidiaries and the reports of the directors and auditors of the company for the year ended 31 December 2016; to re-elect Mr. Wu Xiong as a non-executive director of the company; to re-elect Dr. Ngai Wai Fung as an independent non-executive director of the company; and re-elect Mr. Tan Wee Seng as an independent non-executive director of the company; to authorize the board of directors of the company to fix the remuneration of the directors of the company; to re-appoint Ernst & Young as auditors of the company and to authorize the board to fix their remuneration; to grant a general mandate to the directors to allot, issue and deal with additional shares of the company not exceeding 20% of the total number of issued shares in the capital of the company as at the date of passing of this resolution; and to approve the change of name of the company.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

1112 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1112.
View Industry Companies

Industry Analysis


Industry Average

Valuation 1112 Industry Range
Price/Earnings 12.4x
Price/Sales 1.8x
Price/Book 3.7x
Price/Cash Flow 12.3x
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact BIOSTIME INTERNATIONAL HOLDI, please visit www.biostime.com.cn. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.